ProtoKinetix CEO updates on founder Clarence Smith's passing and AAGP molecule strategy

ProtoKinetix, Inc.

CEO Guzzetta acknowledges sudden passing of longtime leader Clarence Smith and commitment to his vision.
Company continues development of first-in-class synthetic glycopeptide AAGP (PKX-001) for cell protection and inflammation control.
Global patent portfolio covers US, Europe, UK, Asia; outreach to pharma firms for Type 1 Diabetes, cell therapy, dry-eye, and topical applications.
No financial or operational metrics provided; update is a stockholder letter with no specific milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.